These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21155586)

  • 21. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.
    Swinney DC; Beavis P; Chuang KT; Zheng Y; Lee I; Gee P; Deval J; Rotstein DM; Dioszegi M; Ravendran P; Zhang J; Sankuratri S; Kondru R; Vauquelin G
    Br J Pharmacol; 2014 Jul; 171(14):3364-75. PubMed ID: 24628038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
    El-Hage N; Dever SM; Podhaizer EM; Arnatt CK; Zhang Y; Hauser KF
    AIDS; 2013 Sep; 27(14):2181-90. PubMed ID: 23751259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
    Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
    AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
    Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplex detection of functional G protein-coupled receptors harboring site-specifically modified unnatural amino acids.
    Naganathan S; Ray-Saha S; Park M; Tian H; Sakmar TP; Huber T
    Biochemistry; 2015 Jan; 54(3):776-86. PubMed ID: 25524496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
    Mulampaka SN; Dixit NM
    PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
    Bai Q; Zhang Y; Li X; Chen W; Liu H; Yao X
    Phys Chem Chem Phys; 2014 Nov; 16(44):24332-8. PubMed ID: 25296959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
    Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the allosteric modulation of CCR5 function by Maraviroc.
    Lagane B; Garcia-Perez J; Kellenberger E
    Drug Discov Today Technol; 2013; 10(2):e297-305. PubMed ID: 24050281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor.
    Grunbeck A; Huber T; Abrol R; Trzaskowski B; Goddard WA; Sakmar TP
    ACS Chem Biol; 2012 Jun; 7(6):967-72. PubMed ID: 22455376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
    Xu GG; Guo J; Wu Y
    Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5.
    Zhu Y; Zhao YL; Li J; Liu H; Zhao Q; Wu BL; Yang ZL
    Acta Pharmacol Sin; 2019 Apr; 40(4):563-568. PubMed ID: 29941870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.